目的 研究福多司坦片联合布地奈德福莫特罗粉吸入剂治疗稳定期慢性阻塞性肺疾病的临床疗效。方法 选取2016年11月—2018年7月都江堰市人民医院收治的360例稳定期慢性阻塞性肺疾病患者作为研究对象，采用数字表法将患者随机分为对照组和治疗组，每组各180例。对照组给予布地奈德福莫特罗粉吸入剂，1吸/次，2次/d。治疗组在对照组治疗的基础上口服福多司坦片，0.4 g/次，3次/d。两组患者均持续治疗2周。观察两组患者的临床疗效，同时比较两组的圣乔治呼吸问卷（SGRQ）评分、血气指标、肺功能指标和血清学指标。结果 治疗后，对照组和治疗组的总有效率分别为77.8%、91.7%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组肺部症状、活动能力、疾病影响评分和总分均显著降低，同组治疗前后比较差异具有统计学意义（P<0.05）；治疗后，治疗组SGPR评分显著低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者氧分压（pO₂）、1秒钟用力呼气量（FEV₁）/用力肺活量（FVC）、最大呼气流量（PEF）显著升高，二氧化碳分压（pCO₂）均显著降低，同组治疗前后比较差异具有统计学意义（P<0.05）；治疗后，治疗组血气指标和肺功能指标均显著优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者血清白细胞介素-6（IL-6）、白细胞介素-8（IL-8）、丙二醛（MDA）水平均明显降低，对氧磷酶-1（PON1）水平明显增高，同组治疗前后比较差异具有统计学意义（P<0.05）；治疗后，治疗组血清学指标明显优于对照组，两组比较差异具有统计学意义（P<0.05）。结论 福多司坦片联合布地奈德福莫特罗粉吸入剂治疗稳定期慢性阻塞性肺疾病疗效显著，可改善血气和肺功能指标，降低血清炎症因子水平和氧化应激水平，具有一定的临床推广价值。

Objective To study the clinical efficacy of Fudosteine Tablets combined with Budesonide and Formoterol Fumarate Powder for inhalation in treatment of stable chronic obstructive pulmonary disease. Methods Patients (360 cases) with stable chronic obstructive pulmonary disease in Dujiangyan People's Hospital from November 2016 to July 2018 were randomly divided into control and treatment groups, and each group had 180 cases. Patients in the control group were inhalation administered with Budesonide and Formoterol Fumarate Powder for inhalation, 1 suction/time, twice daily. Patients in the treatment group were po administered with Fudosteine Tablets on the basis of the control group, 0.4 g/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, and SGRQ scores, blood gas indexes, lung function indexes, and serological indexes were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 77.8% and 91.7%, and there were differences between two groups (P<0.05). After treatment, the pulmonary symptom, activity ability, disease impact score, and total score in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, the SGRQ scores in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, pO₂, FEV₁/FVC, and PEF in two groups were significantly increased, but pCO₂ in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, blood gas and lung function indexes in the treatment group were significantly better than those in the control group, with difference between two groups (P<0.05). After treatment, IL-6, IL-8, and MDA in two groups were significantly decreased, but PON1 in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). After treatment, the serological indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Fudosteine Tablets combined with Budesonide and Formoterol Fumarate Powder for inhalation has significant clinical effect in treatment of stable chronic obstructive pulmonary disease, can improve the indexes of blood gas and lung function, reduce the serum inflammatory factors and oxidative stress levels, which has a certain clinical application value.